Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma - Summary - MDSpire
From the Journals

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma

A cohort study showed that patients with melanoma who received BRAF or MEK inhibitor therapy commonly experienced hypertension and mild cardiac dysfunction, supporting baseline cardiotoxicity risk str...

  • By

  • Julia Cipriano

  • May 8, 2026

  • 4 min

Share

A recent longitudinal cohort study by Glen et al., published in JACC: CardioOncology, highlights the prevalence of cancer therapy-related cardiac dysfunction and hypertension among melanoma patients undergoing BRAF or MEK inhibitor therapy. The study found that nearly half of the participants developed cardiac dysfunction, with most cases being mild and not worsening over time. Importantly, the risk of serious dysfunction was noted as early as four weeks post-treatment initiation. The authors advocate for baseline risk stratification and routine cardiovascular monitoring to minimize adverse effects while maximizing cancer treatment efficacy.

Original Source(s)

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma

  • by Julia Cipriano

  • May 8, 2026

Related Content

Most Decline Proactive Care Coordination

"Lack of effective communication across physicians is a health system problem."

Bereavement Tied to Higher Cardiovascular Risk

Acute post-loss period and pandemic conditions each amplified cardiovascular vulnerability in nationwide Swedish cohort study

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management